Targeting KDM4C enhances CD8(+) T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer

BACKGROUND: Although immune checkpoint blockade (ICB) has been proven to achieve a persistent therapeutic response in various tumor types, only 20%–40% of patients benefit from this treatment. Radiotherapy (RT) can enhance tumor immunogenicity and improve the ICB response, but the outcome achieved b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jie, Xiaohua, Chen, Yunshang, Zhao, Ye, Yang, Xijie, Xu, Yingzhuo, Wang, Jian, Meng, Rui, Zhang, Sheng, Dong, Xiaorong, Zhang, Tao, Yang, Kunyu, Xu, Shuangbing, Wu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819819/
https://www.ncbi.nlm.nih.gov/pubmed/35121645
http://dx.doi.org/10.1136/jitc-2021-003716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819819/
https://www.ncbi.nlm.nih.gov/pubmed/35121645
http://dx.doi.org/10.1136/jitc-2021-003716

Ejemplares similares